When Knox Singleton first took the helm at Inova Health System in 1984, Mobil Corp. was still building its campus — the first major corporate headquarters ever landed by Fairfax County — on the massive wooded lot just across the street from the health system’s Fairfax hospital.
ConverGene has entered into a Sponsored Research Agreement with University of Maryland, Baltimore. Under this agreement University of Maryland School of Medicine Professor Curt I. Civin, M.D., who is associate dean for research and director of the Center For Stem Cell Biology & Regenerative Medicine, will investigate the in vivo anti-leukemic effects of ConverGene’s lead drug candidates, CG223 and CG250. Acute Myelogenous Leukemia (AML) is a likely first disease target for these compounds.
The company just received a Series A investment from VSP Global, one of the country’s largest networks of vision doctors.
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted “Fast-Track” status for its lead drug CPP-1X/sul for adults with familial adenomatous polyposis (FAP), which is currently in a Phase 3 clinical trial. FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. Currently there is no effective treatment for FAP.
Flagship Pioneering (fka Flagship Ventures), a Cambridge, MA-based life sciences venture capital firm, is seeking to raise $500m for its latest fund.
Congressional lawmakers from both parties have rejected the Trump administration’s proposals to cut spending for NIH, and have joined forces to increase spending on biomedical research.
Developers Taconic Investment Partners and Silverstein Properties are spending $20 million to renovate the 326,861-sf Movie Lab building in Midtown Manhattan for life science research usage.
After holding it in the District for years, the health system is packing up and taking its annual symposium across the country.
Emergent Biosolutions produces cures in Downtown Baltimore for cancer patients, troops and stockpiles in case of a chemical attack.
Fractal Technology, a startup founded at Johns Hopkins, was recently acquired by Annapolis Junction–based Sunayu, according to the cofounders.
